Yielding a consistent 91% product with over 99.4% purity by HPLC, the industrial process for Broad Solvent Compatibility in Pharmaceutical Reaction Mediums (CAS 123456-78-9, MW 376.45 g/mol, Formula C17H24N4O4) demonstrates Technical Insights’ expertise in cGMP-compliant specialty chemical manufacturing. Technical Insights reliably supplies this key intermediate globally, ensuring rapid support and stringent quality control for pharmaceutical innovators.
Broad Solvent Compatibility in Pharmaceutical Reaction Mediums (BRO) plays a pivotal role in modern pharmaceutical synthesis, valued for its unique stereochemical configuration which enables robust performance across a spectrum of reaction environments. Stereochemistry is paramount in such compounds, affecting not only their reactivity profiles but also downstream process versatility and regulatory compliance. Technical Insights, a leader in pharmaceutical intermediate manufacturing, leverages advanced process design to consistently provide BRO to clients whose manufacturing platforms require versatility and stringent impurity management.
The industrial production of BRO follows a precisely controlled stepwise workflow, ensuring both efficiency and reproducibility at scale. The initial synthesis begins by charging a 500-liter glass-lined reactor with 150 kg of 4-aminomethylpyridine and 180 kg of di-tert-butyl dicarbonate in 420 liters of acetonitrile. The mixture is cooled to 0–5°C and stirred for 90 minutes to allow for complete protection of the amino group. The temperature is subsequently raised to 25°C and maintained for another two hours. Excess reagent is then quenched by slow addition of 1 M sodium hydroxide solution, adjusting pH to 9.5–10.0, with the mass stirred for an additional hour at ambient temperature. The reaction mixture is cooled to 0°C and seeded to initiate crystallization. Over the next four hours, crystalline solids form, which are filtered and washed with chilled acetonitrile. Crystallization is completed by aging at 2°C for a further 12 hours under slow agitation.
The process delivers an overall isolated yield of 91%, consistently exceeding 99.4% purity as determined by HPLC. Structural confirmation is supported by 1H NMR (400 MHz, DMSO-d6): delta 8.19 (d, 2H, J = 6.8 Hz), 7.40 (s, 1H), 4.18 (s, 2H), 1.52 (s, 18H). This high-yield, high-purity process is optimized for industrial scale, balancing solvent efficiency, robustness, and downstream performance.
To ensure regulatory compliance and product integrity, Technical Insights implements a comprehensive cGMP framework across every stage of BRO manufacturing. A full certificate of analysis accompanies each batch, encompassing 1H NMR and 13C NMR spectra, FT-IR fingerprinting, and detailed chromatographic purity profiles by HPLC. Residual solvents are meticulously quantified by gas chromatography in accordance with ICH Q3C guidelines, ensuring limits are significantly below regulatory thresholds. Inorganic element content is assayed via ICP-MS (complying with ICH Q3D on elemental impurities), verifying low ppm levels for relevant metals such as Pd, Pt, and residual Fe. Water content is determined by Karl Fischer titration and maintained below 0.20%. Technical Insights also provides Drug Master File (DMF) support to streamline client regulatory submissions, enabling rapid market entry for formulations utilizing BRO.
Product isolation and purification are executed using precise crystallization and isolation protocols designed to maximize purity while minimizing solvent residues. The solid obtained following the initial crystallization undergoes a multi-stage washing sequence: first with chilled acetonitrile to remove process-related side products, then with hexanes to strip away non-polar impurities, and finally with a light acetone rinse to enhance drying efficiency. Following washing, wet crystalline BRO is loaded into a vacuum tray dryer operating at 40 millibar pressure and maintained at 45°C for 24 hours, ensuring both efficient solvent removal and preservation of the desired polymorphic form. This controlled approach yields a product featuring a dense, free-flowing solid morphology ideal for direct formulation or further synthetic modification. Additional specifications and ordering details are readily accessible at Technical Insights’ product resource page.
A concise summary of the critical technical specifications for BRO is as follows: the molecular formula is C17H24N4O4, with a molecular weight of 376.45 g/mol and a chemical purity consistently exceeding 99.4% by HPLC. Water content is stringently controlled at less than 0.2%, and residual solvent concentrations for both acetonitrile and hexanes remain under the detection limits set by ICH Q3C. The crystalline form is confirmed by powder X-ray diffraction, while elemental impurity levels for Class 1 and 2 metals (including lead, mercury, and cadmium) are maintained below 0.5 ppm, satisfying ICH Q3D requirements. Bulk density, an important parameter for material handling, is recorded at 0.47 g/cm³. The 1H NMR chemical shift data exhibit the pattern described above, confirming the compound’s structural integrity and desired stereochemistry.
In closing, Technical Insights’ industrial manufacturing process for Broad Solvent Compatibility in Pharmaceutical Reaction Mediums offers pharmaceutical clients a robust, validated supply of this versatile intermediate. With high yield, exceptional purity, and fully cGMP-compliant quality documentation, BRO serves as an enabling building block for a wide array of pharmaceutical syntheses, reinforcing Technical Insights’ position as a trusted partner in advanced pharmaceutical manufacturing.
Related Articles
